放化疗同步治疗晚期肺癌76例临床分析  

Clinical analysis of radiotherapy concurrent with chemotherapy for advanced lung cancer: a report of 76 cases

作　　者：刘鹏辉[1] 廖国清[1] 王红梅[1] 曲怡梅[1] 李彦敏[2] 

机构地区：[1]解放军总医院第309临床部肿瘤科 [2]中国医科大学附属第一医院放疗科,辽宁沈阳110001

出　　处：《中国医科大学学报》2005年第5期480-481,484,共3页Journal of China Medical University

摘　　要：目的:探讨如何提高晚期肺癌的疗效和生存率。方法:131例晚期肺癌患者非随机分成化疗放疗序贯组和放疗同步化疗组,并将两组的治疗效果和不良反应相比较。结果:序贯组PR为47.3%,1年生存率为38.2%;同步组PR为61.8%,1年生存率为46%;两组相比有显著性差异(P<0.05,χ2检验),序贯组血液学毒性和食管炎低于同步组,两组有显著性差异,余不良反应无显著差异。结论:对晚期肺癌患者,同步组可明显提高肿瘤控制率和1年生存率,不良反应无明显增加。Objective： To evaluate how to improve the therapeutic effect and survival rate of advanced lung cancer. Methods： 131 patients with advanced lung cancer were divided nonrandomly into sequential group and concurrent group. The effect and side effect were compared. Results： In sequential group, partial remission was 47.3% , and one-year survival rate was 38.2%. In concurrent group, partial remission was 61.8% , and one-year survival rate was 46.0%. There were significant differences in partial remission and one-year survival rate between these 2 groups （ P 〈 0.05 ）. The hematologic toxicities and esophagitis were less evident in sequential group than in concurrant group. Other toxicities were similar. Conclusion： In patients with advanced lung cancer, radiotherapy concurrent with chemotherapy can significantly improve the tumor control rate and one-year survival rate without increasing the adverse effect.

关 键 词：晚期肺癌 放疗同步化疗 疗效 不良反应 

分 类 号：R734.2[医药卫生—肿瘤]